Loading clinical trials...
Loading clinical trials...
The purpose of the study is to assess the cumulative disease detection of greater than or equal to Cervical intraepithelial neoplasia 2 (CIN2) and greater than or equal to Cervical intraepithelial neoplasia 3 (CIN3) in the subjects over 3 years using the subject's HPV status and cytology status from the BDS-USHPV baseline results
Age
21 - No limit years
Sex
FEMALE
Healthy Volunteers
Yes
University of Alabama
Birmingham, Alabama, United States
Mobile OB/GYN
Mobile, Alabama, United States
Women's Health Research of Arizona
Phoenix, Arizona, United States
Quality of Life Medical & Research Center
Tucson, Arizona, United States
Visions Clinical Research
Tucson, Arizona, United States
Women's Health Care Research Corp.
San Diego, California, United States
Blueskies Center for Women
Colorado Springs, Colorado, United States
Health Awareness Inc.
Jupiter, Florida, United States
Altus Research
Lake Worth, Florida, United States
Segal Institute for Clinical Research
North Miami, Florida, United States
Start Date
October 1, 2014
Primary Completion Date
December 12, 2018
Completion Date
May 1, 2019
Last Updated
February 8, 2021
6,730
ACTUAL participants
BD HPV Assay on Viper LT
DEVICE
Colposcopy
PROCEDURE
Lead Sponsor
Becton, Dickinson and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06115772